

Keith T Flaherty

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4024628/keith-t-flaherty-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

348
papers

48,972
citations

81
h-index

220
g-index

394
ext. papers

59,990
ext. citations

11.6
avg, IF

7.18
L-index

#	Paper	IF	Citations
348	Randomized Phase III Trial Evaluating Spaltalizumab Plus Dabrafenib and Trametinib for V600-Mutant Unresectable or Metastatic Melanoma.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101601	2.2	10
347	Phase II Study of Copanlisib in Patients With Tumors With Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101648	2.2	4
346	Phase II Study of Taselisib in -Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100424	3.6	1
345	Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma.. <i>Cell Reports Medicine</i> , 2022 , 3, 100500	18	2
344	STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming.. <i>Nature Communications</i> , 2022 , 13, 1859	17.4	1
343	Anti-tumor Activity of a Mitochondrial Targeted HSP90 Inhibitor in Gliomas.. <i>Clinical Cancer Research</i> , 2022 ,	12.9	2
342	Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. <i>Nature Communications</i> , 2021 , 12, 6023	17.4	1
341	Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect. <i>British Journal of Dermatology</i> , 2021 , 185, 253-262	4	8
340	Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805). <i>Clinical Cancer Research</i> , 2021 , 27, 3397-3403	12.9	0
339	Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab153	1	5
338	Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study. <i>Oncologist</i> , 2021 , 26, 731-e1498	5.7	3
337	Pyrexia-related outcomes upon application of an adapted pyrexia management algorithm in patients (pts) with BRAF V600: Mutant unresectable or metastatic melanoma treated with dabrafenib plus trametinib (DabTram) in the COMBI-i trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9560-9560	2.2	2
336	Evolution of delayed resistance to immunotherapy in a melanoma responder. <i>Nature Medicine</i> , 2021 , 27, 985-992	50.5	11
335	Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF Inhibition. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 1317-1324.e1	4.3	5
334	Rejection of benign melanocytic nevi by nevus-resident CD4 T cells. <i>Science Advances</i> , 2021 , 7,	14.3	1
333	Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective. <i>Cancer Discovery</i> , 2021 , 11, 1881-1885	24.4	8
332	Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop. <i>Clinical Cancer Research</i> , 2021 , 27, 394-401	12.9	3

331	A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation. <i>Journal of Translational Medicine</i> , 2021 , 19, 17	8.5	4
330	The State of Melanoma: Emergent Challenges and Opportunities. <i>Clinical Cancer Research</i> , 2021 , 27, 2678-2697	12.9	11
329	Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	22
328	Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial. <i>JAMA Oncology</i> , 2021 , 7, 271-278	13.4	15
327	Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort 2021 , 9,		1
326	Differential Outcomes in Codon 12/13 and Codon 61 -Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with -Mutated Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 2996-3004	12.9	5
325	Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2021 , 80, 20-31	10.2	10
324	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). <i>European Journal of Cancer</i> , 2021 , 152, 116-128	7.5	2
323	Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy. <i>Clinical Cancer Research</i> , 2021 , 27, 5993-6000	12.9	11
322	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. <i>Cancer Research</i> , 2021 , 81, 5230-5241	10.1	1
321	Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. <i>European Journal of Cancer</i> , 2021 , 153, 234-241	7.5	4
320	The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 2018-2027.e4	4.3	1
319	REDCap-Based Operational Tool to Guide Care Coordination in a Multidisciplinary Cutaneous Oncology Clinic. <i>JCO Oncology Practice</i> , 2021 , 17, 527-533	2.3	
318	Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2407-2417	22.2	44
317	SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth. <i>Molecular Cancer Research</i> , 2020 , 18, 1560-1573	6.6	3
316	Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2. <i>Cancer Discovery</i> , 2020 , 10, 1282-1295	24.4	29
315	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. <i>European Journal of Cancer</i> , 2020 , 130, 126-138	7.5	39
314	Tracking early response to immunotherapy.. <i>Nature Cancer</i> , 2020 , 1, 160-162	15.4	6

313	Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10012-10012	2.2	10
312	Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2020 , 132, 112-121	7.5	12
311	Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2020 , 21, 358-372	21.7	49
310	Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. <i>Journal of Urology</i> , 2020 , 203, 684-689	2.5	6
309	A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 460-467	6.1	28
308	Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. <i>European Journal of Cancer</i> , 2020 , 126, 33-44	7.5	74
307	The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 1021-1029	9.7	61
306	Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 214-222	2.2	53
305	Tumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	1
304	Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). <i>Journal of Clinical Oncology</i> , 2020 , 38, 3883-3894	2.2	60
303	Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. <i>Nature Medicine</i> , 2020 , 26, 1557-1563	50.5	41
302	LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial. <i>Annals of Oncology</i> , 2020 , 31, S1172	10.3	36
301	Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials. <i>Journal of Translational Medicine</i> , 2020 , 18, 294	8.5	3
300	Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome. <i>Science Advances</i> , 2020 , 6,	14.3	14
299	Reversal of pre-existing NGFR-driven tumor and immune therapy resistance. <i>Nature Communications</i> , 2020 , 11, 3946	17.4	25
298	Dabrafenib and Trametinib in Patients With Tumors With Mutations: Results of the NCI-MATCH Trial Subprotocol H. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3895-3904	2.2	34
297	SARS-CoV-2 viral load is associated with increased disease severity and mortality. <i>Nature Communications</i> , 2020 , 11, 5493	17.4	360
296	Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma. <i>Clinical Cancer Research</i> , 2020 , 26, 6039-6050	12.9	9

295	Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131). <i>Clinical Cancer Research</i> , 2020 , 26, 1812-1819	12.9	17
294	Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation. <i>Clinical Cancer Research</i> , 2019 , 25, 7202-7217	12.9	18
293	Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600E/K-mutant advanced or metastatic melanoma. <i>European Journal of Cancer</i> , 2019 , 109, 61-69	7.5	18
292	MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in -, and -Mutant Melanomas. <i>Cancer Discovery</i> , 2019 , 9, 526-545	24.4	41
291	Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2062-2071	2.2	45
290	Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib. <i>European Journal of Cancer</i> , 2019 , 116, 45-55	7.5	5
289	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019 , 381, 626-636	59.2	489
288	Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 897-905	7.4	21
287	Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. <i>Molecular Systems Biology</i> , 2019 , 15, e8323	12.2	11
286	Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 549-562	19.4	45
285	Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5 mice. <i>Nature Communications</i> , 2019 , 10, 1492	17.4	58
284	Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2019 , 25, 6511-6523	12.9	30
283	Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2987-2999	2.2	64
282	Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. <i>British Journal of Cancer</i> , 2019 , 121, 522-528	8.7	12
281	PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1CD38 cells and anti-PD-1 resistance. <i>Nature Immunology</i> , 2019 , 20, 1231-1243	19.1	132
280	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. <i>European Journal of Cancer</i> , 2019 , 119, 97-106	7.5	27
279	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology, The</i> , 2019 , 20, e378-e389	21.7	88
278	Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting. <i>Annals of Oncology</i> , 2019 , 30, v543-v544	10.3	2

277	A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of -mutated Melanoma to MAPK Inhibitors. <i>Clinical Cancer Research</i> , 2019 , 25, 6852-6867	12.9	33
276	Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600E mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9512-9512	2.2	11
275	Selective uveal melanoma inhibition with calcium channel blockade. <i>International Journal of Oncology</i> , 2019 , 55, 1090-1096	4.4	4
274	Liquid biopsy using plasma proteomic profiling to reveal predictors of immunotherapy response.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 130-130	2.2	0
273	Angiogenic factor and cytokine analysis among patients with renal cell carcinoma treated with adjuvant VEGFR TKIs.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 586-586	2.2	
272	Prognostic models for advanced melanoma patients treated with anti-PD-1 monotherapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 133-133	2.2	
271	Organ site-specific radiological responses in anti-PD-1 monotherapy treated advanced melanoma patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9552-9552	2.2	
270	A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring Gene Alterations. <i>Clinical Cancer Research</i> , 2019 , 25, 2699-2707	12.9	66
269	Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control. <i>Oncologist</i> , 2019 , 24, 671-679	5.7	19
268	Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2019 , 25, 6098-6106	12.9	11
267	Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. <i>Nature Communications</i> , 2019 , 10, 5157	17.4	29
266	Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. <i>Nature Medicine</i> , 2019 , 25, 1916-1927	50.5	227
265	CMET-33. PHASE II STUDY OF PALBOCICLIB IN BRAIN METASTASES HARBORING CDK PATHWAY ALTERATIONS. <i>Neuro-Oncology</i> , 2019 , 21, vi58-vi59	1	78
264	ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. <i>Cancer Discovery</i> , 2019 , 9, 396-415	24.4	40
263	Response to Immune Checkpoint Antibodies: Not All Responses Are Created Equal. <i>Clinical Cancer Research</i> , 2019 , 25, 910-911	12.9	2
262	A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF /AXL melanoma. <i>Pigment Cell and Melanoma Research</i> , 2019 , 32, 280-291	4.5	20
261	Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. <i>EMBO Molecular Medicine</i> , 2018 , 10,	12	42
260	Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 2467-2472	11.5	82

259	A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. <i>OncImmunology</i> , 2018 , 7, e1423172	7.2	20
258	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. <i>Lancet Oncology, The</i> , 2018 , 19, 310-322	21.7	284
257	First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. <i>Cancer Discovery</i> , 2018 , 8, 184-195	24.4	198
256	Mechanisms of resistance to immune checkpoint inhibitors. <i>British Journal of Cancer</i> , 2018 , 118, 9-16	8.7	576
255	Anti-PD-1 antibody treatment for melanoma. <i>Lancet Oncology, The</i> , 2018 , 19, e219	21.7	7
254	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 603-615	21.7	451
253	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. <i>Clinical Cancer Research</i> , 2018 , 24, 4771-4784	12.9	21
252	A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers. <i>Oncologist</i> , 2018 , 23, 658-e72	5.7	32
251	First-in-human trial of the PI3K-selective inhibitor SAR260301 in patients with advanced solid tumors. <i>Cancer</i> , 2018 , 124, 315-324	6.4	21
250	When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age. <i>Annals of Internal Medicine</i> , 2018 , 169, 233-239	8	15
249	Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials. <i>JAMA Oncology</i> , 2018 , 4, 1382-1388	13.4	42
248	Toward Minimal Residual Disease-Directed Therapy in Melanoma. <i>Cell</i> , 2018 , 174, 843-855.e19	56.2	256
247	Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. <i>Nature Medicine</i> , 2018 , 24, 1545-1549	50.5	230
246	Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. <i>JCI Insight</i> , 2018 , 3,	9.9	67
245	Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 100-100	2.2	16
244	Results from molecular analysis for therapy choice (MATCH) arm I: Taselisib for PIK3CA-mutated tumors.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 101-101	2.2	23
243	Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2503-2503	2.2	21
242	Autoimmune genetic variants as germline biomarkers of response in melanoma immunotherapy treatment.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3079-3079	2.2	2

241	Characterization of immune related hepatitis (irH) from immune checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3087-3087	2.2	2
240	Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9504-9504	2.2	19
239	Immune checkpoint inhibition (ICI) in advanced cutaneous squamous cell carcinoma (cSCC): Clinical response and correlative biomarker analysis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9564-9564	2.2	5
238	Adverse events of special interest in the phase 3 COLUMBUS study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9567-9567	2.2	2
237	Safety and efficacy of the selective FGFR inhibitor debio 1347 in phase I study patients with FGFR genomically activated advanced biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 447-447	2.2	7
236	Distinct histone modifications denote early stress-induced drug tolerance in cancer. <i>Oncotarget</i> , 2018 , 9, 8206-8222	3.3	39
235	Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockade.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3074-3074	2.2	1
234	Phylogenetic analysis of longitudinal melanoma samples to reveal convergent evolution and markers of immunotherapy resistance.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9581-9581	2.2	
233	Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. <i>Cancer Discovery</i> , 2018 , 8, 196-215	24.4	228
232	Melanoma in 2017: Moving treatments earlier to move further forwards. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 75-76	19.4	7
231	Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2018 , 36, 667-673	2.2	138
230	Emerging Strategies in Systemic Therapy for the Treatment of Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 751-751	7.1	20
229	CMET-16. THE ROLE OF SURGICAL RESECTION OF MELANOMA BRAIN METASTASES IN THE IMMUNOTHERAPY ERA. <i>Neuro-Oncology</i> , 2018 , 20, vi56-vi57	1	78
228	Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. <i>Melanoma Research</i> , 2018 , 28, 605-610	3.3	18
227	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. <i>Cell</i> , 2018 , 175, 984-997.e24	56.2	477
226	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. <i>Cell</i> , 2018 , 175, 998-1013.e20	56.2	631
225	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 1315-1327	21.7	291
224	Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series. <i>Journal of Vascular and Interventional Radiology</i> , 2018 , 29, 1369-1375	2.4	26

223	High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. <i>Cancer</i> , 2018 , 124, 3706-3714	6.4	213
222	MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. <i>Pigment Cell and Melanoma Research</i> , 2017 , 30, 328-338	4.5	23
221	Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. <i>JAMA Oncology</i> , 2017 , 3, 1249-1252	13.4	84
220	Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 435-445	21.7	240
219	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. <i>Annals of Oncology</i> , 2017 , 28, 1631-1639	10.3	361
218	Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. <i>Cancer Research</i> , 2017 , 77, 2318-2327	10.1	153
217	Oncogenic RAS Regulates Long Noncoding RNA in Human Cancer. <i>Cancer Research</i> , 2017 , 77, 3745-3757	10.1	25
216	Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. <i>Clinical Cancer Research</i> , 2017 , 23, 4680-4692	12.9	4
215	An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. <i>Journal of Experimental Medicine</i> , 2017 , 214, 1691-1710	16.6	51
214	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , 2017 , 82, 45-55	7.5	114
213	Dabrafenib plus trametinib in patients with BRAF-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 863-873	21.7	389
212	Targeted agents and immunotherapies: optimizing outcomes in melanoma. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 463-482	19.4	654
211	Academic Cancer Center Phase I Program Development. <i>Oncologist</i> , 2017 , 22, 369-374	5.7	
210	Resistance to checkpoint blockade therapy through inactivation of antigen presentation. <i>Nature Communications</i> , 2017 , 8, 1136	17.4	409
209	PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. <i>Nature</i> , 2017 , 550, 133-136	50.4	100
208	Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2017 , 67, 472-492	220.7	1044
207	Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. <i>European Journal of Cancer</i> , 2017 , 83, 247-257	7.5	181
206	Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. <i>Nature Communications</i> , 2017 , 8, 607	17.4	80

205	Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. <i>Science</i> , 2017 , 357, 1156-1160	33.3	577
204	Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. <i>EMBO Molecular Medicine</i> , 2017 , 9, 1011-1029	12	49
203	BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma. <i>Clinical Cancer Research</i> , 2017 , 23, 6203-6214	12.9	22
202	A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. <i>Cancer Medicine</i> , 2017 , 6, 1904-1914	4.8	13
201	Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. <i>Annals of Oncology</i> , 2017 , 28, 2581-2587	10.3	129
200	Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. <i>Cell Reports</i> , 2017 , 21, 2796-2812	10.6	46
199	Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results. <i>Oncologist</i> , 2017 , 22, 1429-e139	5.7	29
198	Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. <i>Cell Reports</i> , 2017 , 21, 1936-1952	10.6	45
197	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. <i>Cell Reports</i> , 2017 , 21, 1953-1967	10.6	89
196	Tissue-Agnostic Drug Development. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 222-230	7.1	12
195	Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings. <i>Radiographics</i> , 2017 , 37, 2132-2144	5.4	68
194	Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2500-2500	2.2	10
193	First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2508-2508	2.2	11
192	Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3057-3057	2.2	21
191	Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9512-9512	2.2	5
190	A phase Ib study of napabucasin plus weekly paclitaxel in patients with advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9553-9553	2.2	3
189	Impact of gene expression profiles on clinical predictors of survival in patients (pts) with BRAFV600-mutated metastatic melanoma (mM).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9556-9556	2.2	5
188	Inflammatory arthritis: An under-recognized immune-relate adverse effect.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e14565-e14565	2.2	1

187	Necuparanib combined with nab-paclitaxel + gemcitabine in patients with metastatic pancreatic cancer: Phase 2 results.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 370-370	2.2	5
186	Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. <i>Oncotarget</i> , 2017 , 8, 25395-25417	3.3	46
185	ASN003, a highly selective BRAF and PI3K inhibitor: Preclinical and phase 1 clinical data in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e14102-e14102	2.2	
184	Expression quantitative trait loci (eQTLs) as germline determinants of melanoma immunotherapy response.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3017-3017	2.2	
183	In the pipeline: encorafenib and binimetinib in BRAF-mutated melanoma. <i>Clinical Advances in Hematology and Oncology</i> , 2017 , 15, 745-747	0.6	4
182	Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. <i>Clinical Cancer Research</i> , 2016 , 22, 374-82	12.9	28
181	High-Throughput Testing of Novel-Novel Combination Therapies for Cancer: An Idea Whose Time Has Come. <i>Cancer Discovery</i> , 2016 , 6, 956-62	24.4	6
180	MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB. <i>Clinical Cancer Research</i> , 2016 , 22, 6088-6098	12.9	30
179	PIPELINES: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms. <i>Clinical Pharmacology and Therapeutics</i> , 2016 , 100, 713-729	6.1	24
178	Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. <i>Lancet Oncology, The</i> , 2016 , 17, 1743-1754	21.7	205
177	An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. <i>Clinical Cancer Research</i> , 2016 , 22, 5204-5210	12.9	11
176	Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer. <i>JAMA Ophthalmology</i> , 2016 , 134, 855-62	3.9	43
175	PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo. <i>Clinical Cancer Research</i> , 2016 , 22, 5818-5828	12.9	53
174	Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2016 , 34, 871-8	2.2	206
173	Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance. <i>Cancer Discovery</i> , 2016 , 6, 382-99	24.4	113
172	Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. <i>Cancer Cell</i> , 2016 , 29, 270-284	24.3	149
171	Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival. <i>Journal of Investigative Dermatology</i> , 2016 , 136, 1002-1011	4.3	40
170	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. <i>Onc Immunology</i> , 2016 , 5, e1136044	7.2	42

169	A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors. <i>Cancer Biology and Therapy</i> , 2016 , 17, 778-84	4.6	7
168	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. <i>Lancet, The</i> , 2016 , 387, 2008-16	4.0	374
167	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. <i>European Journal of Cancer</i> , 2016 , 53, 125-34	7.5	115
166	Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. <i>Clinical Cancer Research</i> , 2016 , 22, 567-74	12.9	151
165	Association of plasma exosomal mRNA changes with long-term durable response to ipilimumab (IPI) in metastatic melanoma (MM) patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3037-3037	2.2	2
164	Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3502-3502	2.2	90
163	Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Updated phase 1 results.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4117-4117	2.2	1
162	Pseudoprogression in cancer immunotherapy: Rates, time course and patient outcomes.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6580-6580	2.2	48
161	Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9500-9500	2.2	22
160	Identifying prognostic subgroups for outcomes in BRAFV600-mutated metastatic melanoma patients (pts) treated with vemurafenib (V) ± cobimetinib (C): A pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9536-9536	2.2	3
159	The impact of obesity on outcomes in metastatic melanoma (MM) patients (pts) treated with dabrafenib and trametinib.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9566-9566	2.2	1
158	NCI-MATCH (Molecular Analysis for Therapy Choice) [a] national signal finding trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS2606-TPS2606	2.2	5
157	Discovery and clinical introduction of first-in-class imipridone ONC201. <i>Oncotarget</i> , 2016 , 7, 74380-74392,3	3.3	83
156	A multivariate analysis of prognostic factors from assure (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 618-618	2.2	
155	Functional characterization of non-V600 BRAF mutations and their response to Trametinib (Tram).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9537-9537	2.2	
154	Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. <i>Cancer Discovery</i> , 2016 , 6, 740-53	24.4	397
153	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. <i>Nature</i> , 2016 , 532, 250-4	50.4	205
152	Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. <i>Science</i> , 2016 , 352, 189-96	33.3	1961

151	The Conundrum of Genetic "Drivers" in Benign Conditions. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	89
150	Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. <i>Clinical Cancer Research</i> , 2016 , 22, 4452-65.	2.9	70
149	Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities. <i>Clinical Cancer Research</i> , 2016 , 22, 6031-6038	12.9	11
148	Biomarkers in Melanoma: Lessons from Translational Medicine. <i>Trends in Cancer</i> , 2016 , 2, 305-312	12.5	6
147	Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. <i>Nature Medicine</i> , 2016 , 22, 1056-61	50.5	49
146	The state of melanoma: challenges and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2016 , 29, 404-16	4.5	63
145	Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. <i>Cancer Discovery</i> , 2015 , 5, 264-73	24.4	61
144	Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma. <i>Melanoma Management</i> , 2015 , 2, 133-147	2.1	2
143	Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 491-9.e2	4.5	10
142	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015 , 51, 833-40	7.5	60
141	Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma. <i>Clinical Cancer Research</i> , 2015 , 21, 2892-7	12.9	27
140	MITF Modulates Therapeutic Resistance through EGFR Signaling. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 1863-1872	4.3	56
139	When are signal transduction targeted therapies acting as immunotherapy?. <i>Cancer Biology and Therapy</i> , 2015 , 16, 645-7	4.6	1
138	Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. <i>Lancet Oncology</i> , 2015 , 16, 1389-98	21.7	162
137	Precision medicine for cancer with next-generation functional diagnostics. <i>Nature Reviews Cancer</i> , 2015 , 15, 747-56	31.3	356
136	Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells. <i>Pigment Cell and Melanoma Research</i> , 2015 , 28, 184-95	4.5	61
135	The E3 ligase APC/C(Cdh1) promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growth. <i>Science Signaling</i> , 2015 , 8, ra87	8.8	15
134	Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials. <i>Lancet Oncology</i> , 2015 , 16, e522-6	21.7	17

133	BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 3115-3124	4.3	61
132	A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma. <i>Oncologist</i> , 2015 , 20, 617-8	5.7	8
131	Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy. <i>JAMA Oncology</i> , 2015 , 1, 1340-1	13.4	46
130	Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. <i>Cell</i> , 2015 , 162, 1242-56	56.2	365
129	Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. <i>Clinical Cancer Research</i> , 2015 , 21, 5215-21	12.9	13
128	Improved overall survival in melanoma with combined dabrafenib and trametinib. <i>New England Journal of Medicine</i> , 2015 , 372, 30-9	59.2	1723
127	Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma. <i>Experimental Dermatology</i> , 2015 , 24, 657-8	4	7
126	Targeted Therapy in Melanoma 2015 , 231-239		
125	Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR. <i>Nature Medicine</i> , 2015 , 21, 741-50	50.5	75
124	Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. <i>European Journal of Cancer</i> , 2015 , 51, 1435-43	7.5	52
123	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2015 , 386, 444-51	40	926
122	New strategies in melanoma: entering the era of combinatorial therapy. <i>Clinical Cancer Research</i> , 2015 , 21, 2424-35	12.9	27
121	BMET-04LEPTOMENINGEAL CARCINOMATOSIS IN MELANOMA. <i>Neuro-Oncology</i> , 2015 , 17, v45.4-v45	1	78
120	Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. <i>Cancer Cell</i> , 2015 , 28, 773-784	24.3	250
119	Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. <i>Cell Reports</i> , 2015 , 11, 1458-73	10.6	37
118	The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. <i>Nature Genetics</i> , 2015 , 47, 250-6	36.3	320
117	EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. <i>Cancer Discovery</i> , 2015 , 5, 274-87	24.4	77
116	Expanded access programmes: patient interests versus clinical trial integrity. <i>Lancet Oncology, The</i> , 2015 , 16, 15-7	21.7	9

115	Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/Kmutation-positive cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 102-102	2.2	2
114	Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2506-2506 ¹⁰	2.2	2
113	First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2564-2564	2.2	4
112	Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3615-3615	2.2	4
111	Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Phase 1 results.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4114-4114	2.2	2
110	Dose analysis of ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4508-4508	2.2	2
109	Plasma-based monitoring of BRAF mutations during therapy for malignant melanoma (MM) using combined exosomal RNA and cell-free DNA analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9017-9017	2.2	5
108	Updated overall survival (OS) results for BRF113220, a phase III study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9036-9036	2.2	12
107	A phase II study of combined therapy with vemurafenib (vem) and high-dose interleukin-2 (aldesleukin; HD IL-2) in patients with metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20074-e20074 ¹	2.2	7
106	Profiling exosomal mRNAs in patients undergoing immunotherapy for malignant melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e22159-e22159	2.2	4
105	Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 403-403	2.2	17
104	Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. <i>PLoS ONE</i> , 2015 , 10, e0140310	3.7	25
103	Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma. <i>Oncotarget</i> , 2015 , 6, 40535-56	3.3	38
102	Detection of low abundant somatic mutations in circulating exosomal RNA and cfDNA with next-generation sequencing.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 11061-11061	2.2	
101	Palliative care and hospice use among melanoma patients treated with immunotherapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 116-116	2.2	
100	New drugs in development for melanoma. <i>Clinical Advances in Hematology and Oncology</i> , 2015 , 13, 717-9.6		
99	Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3697-704	2.2	158
98	Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. <i>New England Journal of Medicine</i> , 2014 , 371, 1877-88	59.2	1195

97	A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. <i>Cancer Discovery</i> , 2014 , 4, 816-27	24.4	338
96	Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. <i>Clinical Cancer Research</i> , 2014 , 20, 3328-37	12.9	30
95	Cyclin-dependent kinases as therapeutic targets in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2014 , 27, 351-65	4.5	18
94	Bevacizumab plus ipilimumab in patients with metastatic melanoma. <i>Cancer Immunology Research</i> , 2014 , 2, 632-42	12.5	428
93	Isolation and molecular characterization of circulating melanoma cells. <i>Cell Reports</i> , 2014 , 7, 645-53	10.6	81
92	Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology</i> , 2014 , 15, 323-32	21.7	753
91	Commentary: Molecular testing in melanoma. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 863-70	4.5	4
90	Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 3210-8	6.1	20
89	Universes collide: combining immunotherapy with targeted therapy for cancer. <i>Cancer Discovery</i> , 2014 , 4, 1377-86	24.4	62
88	One Hippo and many masters: differential regulation of the Hippo pathway in cancer. <i>Biochemical Society Transactions</i> , 2014 , 42, 816-21	5.1	11
87	Major therapeutic developments and current challenges in advanced melanoma. <i>British Journal of Dermatology</i> , 2014 , 170, 36-44	4	18
86	Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma. <i>JAMA Dermatology</i> , 2014 , 150, 307-11	5.1	38
85	The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNF β . <i>Cancer Discovery</i> , 2014 , 4, 1214-1229	24.4	139
84	Systematic identification of signaling pathways with potential to confer anticancer drug resistance. <i>Science Signaling</i> , 2014 , 7, ra121	8.8	117
83	Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. <i>Cancer Immunology Research</i> , 2014 , 2, 643-54	12.5	190
82	Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. <i>PLoS ONE</i> , 2014 , 9, e101286	3.7	35
81	Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. <i>Lancet Oncology</i> , 2014 , 15, 297-304	21.7	49
80	Prognostic and predictive role of circulating angiopoietin-2 in multiple solid tumors: An analysis of approximately 500 patients treated with lenvatinib across tumor types.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11061-11061	2.2	2

79	LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 534-534	2.2	22
78	Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8026-8026	2.2	21
77	Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9010-9010	2.2	11
76	COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8041-8041	2.2	26
75	First-in-human phase I Basket Study of Debio1347 (CH5183284), a novel FGFR inhibitor, in patients with FGFR genomically activated advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS2629-TPS2629	2.2	2
74	NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated or progressed after first-line immunotherapy unresectable or metastatic NRAS-mutant cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS9102-TPS9102	2.2	2
73	An active learning approach for rapid characterization of endothelial cells in human tumors. <i>PLoS ONE</i> , 2014 , 9, e90495	3.7	19
72	Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS9105-TPS9105	2.2	
71	microRNA (miRNA) expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy (CP) in metastatic melanoma (MM) treated on the intergroup trial E2603.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9048-9048	2.2	
70	Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinib.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9062-9062	2.2	
69	ONC201, a small molecule Foxo3a activator, activity against patient-derived glioblastoma tumor-initiating cells.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e13022-e13022	2.2	
68	The effect and mechanism of M402 on gemcitabine uptake into pancreatic tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 215-215	2.2	
67	A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. <i>Nature</i> , 2013 , 504, 138-42	50.4	333
66	BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. <i>Clinical Cancer Research</i> , 2013 , 19, 1225-1231	13.9	679
65	Resistance to BRAF-targeted therapy in melanoma. <i>European Journal of Cancer</i> , 2013 , 49, 1297-304	7.5	273
64	BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. <i>Clinical Cancer Research</i> , 2013 , 19, 393-403	12.9	263
63	Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1767-74	2.2	295
62	Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 373-9	2.2	167

61	A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2500-2500	2.2	35
60	BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9005-9005	2.2	11
59	Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9010-9010	2.2	97
58	Whole exome and whole transcriptome sequencing in melanoma patients to identify mechanisms of resistance to combined RAF/MEK inhibition.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9015-9015	2.2	3
57	Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9016-9016	2.2	2
56	Tumor-specific circulating cell-free DNA (cfDNA) to predict clinical outcome in BRAF V600 mutation-positive melanoma patients (pts) treated with the MEK inhibitor trametinib (T) or chemotherapy (C).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9020-9020	2.2	1
55	A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9026-9026	2.2	4
54	Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9028-9028	2.2	24
53	Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9029-9029	2.2	23
52	Analysis of serum biomarkers and tumor genetic alterations from a phase II study of lenvatinib in patients with advanced BRAF wild-type melanoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9058-9058	2.2	2
51	Efficacy, safety, and pharmacokinetics (PK) of the BRAF inhibitor dabrafenib (D) hydroxypropyl methylcellulose (HPMC) capsule formulation in combination with the MEK1/2 inhibitor trametinib (T) in patients (pts) with BRAF mutation-positive metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9066-9066	2.2	1
50	A phase I study of the combination of sorafenib (Sor) and bortezomib (Bor) in patients (pts) with metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9076-9076	2.2	2
49	Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9094-9094	2.2	5
48	Increase in blood pressure with sorafenib exposure: Renal cell carcinoma (RCC) versus other solid tumors.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e15564-e15564	2.2	1
47	Medical oncologists' clinical experiences and comfort levels with 20 recently approved agents.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e17570-e17570	2.2	1
46	The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e20050-e20050	2.2	2
45	The BEST trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 345-345	2.2	10
44	Increase in blood pressure with sorafenib exposure in renal cell carcinoma versus other solid tumors.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 384-384	2.2	

43	Survival patterns following brain metastases for patients with melanoma in the targeted therapy era.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9064-9064	2.2	
42	Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 533-533	2.2	
41	Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 145-145	2.2	
40	Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. <i>New England Journal of Medicine</i> , 2012 , 367, 1694-703	59.2	2048
39	Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. <i>New England Journal of Medicine</i> , 2012 , 366, 707-14	59.2	1697
38	Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets. <i>Clinical and Experimental Metastasis</i> , 2012 , 29, 841-6	4.7	14
37	From genes to drugs: targeted strategies for melanoma. <i>Nature Reviews Cancer</i> , 2012 , 12, 349-61	31.3	275
36	Improved survival with MEK inhibition in BRAF-mutated melanoma. <i>New England Journal of Medicine</i> , 2012 , 367, 107-14	59.2	1634
35	Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. <i>Nature</i> , 2012 , 487, 500-4	50.4	1308
34	Targeting metastatic melanoma. <i>Annual Review of Medicine</i> , 2012 , 63, 171-83	17.4	47
33	EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. <i>Cancer Discovery</i> , 2012 , 2, 227-35	24.4	663
32	M402, a heparan sulfate mimetic and novel candidate for the treatment of pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4056-4056	2.2	2
31	Cardiac safety analysis for a phase III trial of sunitinib (SU) or sorafenib (SO) or placebo (PLC) in patients (pts) with resected renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4500-4500 ^{2.2}	2.2	4
30	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8502-8502	2.2	65
29	Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAFV600E melanoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8503-8503	2.2	14
28	Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8510-8510	2.2	31
27	Predicting early relapse in patients with BRAFV600E melanoma with a highly sensitive blood BRAF assay.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8516-8516	2.2	1
26	Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8569-8569	2.2	17

25	METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1BA8509-1BA8509	2.2	10
24	New options and new questions: how to select and sequence therapies for patients with metastatic melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012 , 524-30	7.1	2
23	Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8526-8526	2.2	
22	Association of the activation of the mTOR pathway with prognosis in Chinese melanoma patients.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8561-8561	2.2	
21	A single-arm, open-label, U.S. expanded access study of vemurafenib in patients with metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8567-8567	2.2	
20	METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAFV600/k mutant advanced or metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1BA8509-1BA8509	2.2	5
19	mTOR pathway activation in KIT-mutated melanoma with acquired imatinib resistance.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8562-8562	2.2	
18	Improved survival with vemurafenib in melanoma with BRAF V600E mutation. <i>New England Journal of Medicine</i> , 2011 , 364, 2507-16	59.2	5851
17	Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research Congress. <i>Pigment Cell and Melanoma Research</i> , 2011 , 24, 107-9	4.5	5
16	RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). <i>Nature</i> , 2011 , 480, 387-90	50.4	1107
15	BRAF inhibitors and melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2011 , 17, 505-11	2.2	23
14	Is it good or bad to find a BRAF mutation?. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1229-30	2.2	9
13	New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advances. <i>Clinical Cancer Research</i> , 2011 , 17, 4922-8	12.9	32
12	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. <i>Nature</i> , 2010 , 467, 596-9	50.4	1379
11	COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. <i>Nature</i> , 2010 , 468, 968-72	50.4	1162
10	Inhibition of mutated, activated BRAF in metastatic melanoma. <i>New England Journal of Medicine</i> , 2010 , 363, 809-19	59.2	2871
9	Mutation-driven drug development in melanoma. <i>Current Opinion in Oncology</i> , 2010 , 22, 178-83	4.2	77
8	Narrative review: BRAF opens the door for therapeutic advances in melanoma. <i>Annals of Internal Medicine</i> , 2010 , 153, 587-91	8	27

7	Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma. <i>Biochemical Pharmacology</i> , 2010 , 80, 638-46	6	15
6	BRAF, a target in melanoma: implications for solid tumor drug development. <i>Cancer</i> , 2010 , 116, 4902-136.4		92
5	Advances in drug development. BRAF validation in melanoma. <i>Clinical Advances in Hematology and Oncology</i> , 2010 , 8, 31-4	0.6	8
4	A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). <i>Cancer Causes and Control</i> , 2005 , 16, 1099-106	2.8	99
3	SARS-CoV-2 Viral Load is Associated with Increased Disease Severity and Mortality		10
2	SARS-CoV-2 Viral Load is Associated with Increased Disease Severity and Mortality		4
1	Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma		1